



# Ovarian Cancer

## Quick Reference Guide

2026

## Table of Contents

|                                                              |           |
|--------------------------------------------------------------|-----------|
| <b>1. CLINICAL SNAPSHOT .....</b>                            | <b>3</b>  |
| HCC/RAF V28 Mapping .....                                    | 3         |
| <b>2. RECOGNITION AND DIAGNOSIS .....</b>                    | <b>4</b>  |
| Medicare Screenings (older adults, at-risk population) ..... | 4         |
| Subtle Early Signs in Older Adults (>65) .....               | 5         |
| Geriatric Risk Factors .....                                 | 6         |
| Diagnostic Thresholds .....                                  | 6         |
| Common Oversights .....                                      | 7         |
| Key Differentials in Elderly .....                           | 8         |
| Comorbidity Screening .....                                  | 8         |
| Staging/Severity Matrix .....                                | 9         |
| <b>3. MEAT DOCUMENTATION ESSENTIALS .....</b>                | <b>10</b> |
| Clinical Documentation Elements .....                        | 11        |
| Reframing Common Documentation Shortcuts .....               | 11        |
| <b>4. TREATMENT AND REFERRAL QUICK GUIDE .....</b>           | <b>12</b> |
| Therapy Escalation Criteria .....                            | 12        |
| Aligned Recommendations .....                                | 13        |
| Non-Pharmacologic Treatment and Lifestyle Modification ..... | 13        |
| Medication Safety and Dose Adjustments .....                 | 14        |
| When to Refer .....                                          | 15        |
| Follow-Up Timing .....                                       | 15        |
| Comorbidity Management .....                                 | 16        |
| Cost-Smart Options .....                                     | 16        |
| Patient Education and Adherence .....                        | 17        |
| Quality Metrics Tie-In .....                                 | 18        |
| <b>5. CODING REMINDERS AND CASE EXAMPLES .....</b>           | <b>19</b> |
| Documentation Specificity .....                              | 19        |
| Annual Clinical Review and Confirmation .....                | 20        |
| Good Documentation is Comprehensive Coding .....             | 20        |
| EHR Workflow Tips .....                                      | 21        |
| Brief Case Examples .....                                    | 21        |
| <b>REFERENCES .....</b>                                      | <b>22</b> |

# 1 CLINICAL SNAPSHOT

**Definition:** Malignant neoplasm of the ovary, fallopian tube, or peritoneum — predominantly epithelial in origin, with high-grade serous carcinoma the most common histologic subtype. No validated population screening test exists; approximately 80% of cases are diagnosed at FIGO Stage III or IV.<sup>1</sup> Median age at diagnosis is 63 years.<sup>1</sup>

## ICD-10 Codes:

Primary ovary **C56.1** (right)/**C56.2** (left)/**C56.3** (bilateral)/**C56.9** (unspecified — avoid); primary peritoneal **C48.0–C48.8** (distinct entity, **not C56**). **Metastatic sites: C78.6 peritoneum, C78.7 liver, C78.0x lung, C78.89 omentum/intestine, C79.31 brain** (each maps to HCC 17); **C79.51 bone** (HCC 18). Code each metastatic site individually.

**Prevalence:** ACS projects ~21,010 new diagnoses<sup>2</sup> and ~12,450 deaths<sup>2</sup> in the U.S. in 2026; lifetime risk ~1.3%.<sup>2</sup> Approximately 50% of patients are aged ≥65<sup>3</sup> at diagnosis — the core Medicare population. 5-year relative survival: Stage I 92%; Stage II 72%; Stage III–IV 27%.<sup>4</sup>

## HCC/RAF V28 Mapping

| ICD-10 CODE <sup>1–3</sup>                                                                                     | HCC CATEGORY                                                      | RAF WEIGHT | DOCUMENTATION REQUIREMENT                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>C56.1, C56.2, C56.3 (Malignant neoplasm of ovary)</b>                                                       | HCC 23 —<br>Prostate, Breast,<br>other Cancers<br>and Tumors      | 0.186      | <b>Primary ovarian cancer</b> with documented <b>laterality</b> from pathology or imaging. <b>C56.9 reduces specificity</b> and is discouraged             |
| <b>C78.6, C78.7, C78.0x, C78.89, C79.31 (Secondary malignant neoplasm of respiratory and digestive organs)</b> | HCC 17 —<br>Cancer<br>Metastatic to<br>Lung/Liver/Brain/<br>Other | 4.209      | Metastatic spread to <b>peritoneum, liver, lung, omentum/intestine, or brain</b> . Each site coded <b>individually</b> with imaging or pathologic evidence |
| <b>C79.51 (Secondary malignant neoplasm of bone)</b>                                                           | HCC 18 —<br>Cancer<br>Metastatic to<br>Bone/Other                 | 2.341      | <b>Bone metastasis</b> ; document <b>specific bone site</b> (e.g., vertebral, femur) when available                                                        |
| <b>C79.60, C79.61, C79.62 (Secondary malignant neoplasm of other and unspecified sites)</b>                    | HCC 18 —<br>Cancer<br>Metastatic to<br>Bone/Other                 | 2.341      | <b>Metastasis to the ovary from another primary</b> ; documented laterality preferred                                                                      |

# AAVBC Knowledge Hub Premium Content Access

Continue reading your guide  
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

## Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time